← Back to headlines
Guggenheim Sees Favorable Risk-Reward for Pfizer Ahead of Phase 3 Data
Guggenheim analysts have identified a favorable risk-reward scenario for Pfizer's stock (PFE) as the company approaches the release of its Phase 3 clinical trial data.
27 Mar, 01:15 — 27 Mar, 01:15
Sources
Showing 1 of 1 sources
